GTC Biotherapeutics (fka GTCB)

[keitern]

I heard an interesting take on PIII trials yesterday from the CFO of a biotech company. The statement was that PIII trials should seldom fail. The idea was that if a company does its homework correctly and does the upfront work required, they should be able to minimize the risk of non-approval. If this is true, I hope GTCB takes it time and does the Atryn US trial in a manner that reduces risk appropriately and gives us the best chance for success.